Results 111 to 120 of about 16,645 (269)

Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy

BMC Nephrology
Background To evaluate the clearance of edoxaban during modeled in vitro continuous renal replacement therapy (CRRT), assess protein binding and circuit adsorption, and provide initial dosing recommendations.
Eric Wenzler, Kaitlyn Dalton, Lauren Andrews, Scott T. Benken   +3 more
doaj   +1 more source

Edoxaban treatment in a post-infarction experimental model

European Journal of Pharmacology
The sequelae of myocardial infarction (MI) require specific pharmacological therapy to minimise the post-MI remodelling, which in many cases evolves into cardiovascular complications. The aim of this study was to analyse the effect of edoxaban, an oral anticoagulant, on cardiac recovery in a rat model of permanent coronary artery ligation.An ...
Javier Martínez-Fernández, Cristina Almengló, Borja Babarro, Ramón Iglesias-Rey, Tomás García-Caballero, Ángel L. Fernández, Miguel Souto-Bayarri, José R. González-Juanatey, Ezequiel Álvarez   +8 more
openaire   +4 more sources

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy

ESC Heart Failure, 2019
Extensive data support the safety of direct oral anticoagulants compared with vitamin K antagonists in patients with non‐valvular atrial fibrillation, leading to a significantly increase in the use of these compounds in clinical practice.
Mattia Galli, Domenico D'Amario, Felicita Andreotti, Italo Porto, Rocco Vergallo, Mario Sabatelli, Stefano Lancellotti, Emiliana Meleo, Raimondo De Cristofaro, Filippo Crea   +9 more
doaj   +1 more source

In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution

Drugs in R&D, 2020
Background and Objective Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral ...
Alexandra A. Angheloiu, Yanglan Tan, Cristian Ruse, Scott A. Shaffer, George O. Angheloiu   +4 more
doaj   +1 more source

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundWe studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). Methods and ResultsENGAGE AF‐TIMI 48 was a randomized trial that compared 2
Haiyan Xu, Christian T. Ruff, Robert P. Giugliano, Sabina A. Murphy, Francesco Nordio, Indravadan Patel, Minggao Shi, Michele Mercuri, Elliott M. Antman, Eugene Braunwald   +9 more
doaj   +1 more source

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation [PDF]

, 2010
Hui‐Kyung Jeon, Li‐Ming Lien, Wen-Ter Lai, Hung‐Fat Tse, Wook-Sung Chung, Tsong-Hai Lee, Shih-Ann Chen, Namsik Chung   +7 more
openalex   +1 more source

Anticoagulant activity of edoxaban in patients with cirrhosis [PDF]

Blood, 2020
Sarah Bos, Tim Schreuder, Hans Blokzijl, Jelle Adelmeijer, Ton Lisman, Pieter W. Kamphuisen   +5 more
openaire   +3 more sources

Edoxaban Monotherapy and Incidence of Transcatheter Heart Valve Leaflet Thrombosis — The Rotterdam Edoxaban (REDOX) Study

Catheterization and Cardiovascular Interventions
ABSTRACTBackgroundTrials comparing non‐vitamin K oral anticoagulant (NOAC) versus antiplatelet‐based strategies have shown a reduction of subclinical leaflet thrombosis at the cost of increased mortality and major‐bleedings. NOACs were often combined with antiplatelet therapy.AimsThe Rotterdam Edoxaban (REDOX) study aimed to evaluate the impact of ...
Rik Adrichem, Maarten P. van Wiechen, Wiebe G. Knol, Thijmen W. Hokken, Joris F. Ooms, Mark M. P. van den Dorpel, Sarah Verhemel, Isabella Kardys, Rutger‐Jan Nuis, Joost Daemen, Alexander Hirsch, Ricardo P. J. Budde, Nicolas M. Van Mieghem   +12 more
openaire   +3 more sources

Direkt orális antikoagulánsok a kardiológiában | Direct oral anticoagulants in cardiology [PDF]

, 2016
Absztrakt Az antithromboticus gyógyszeres kezelés napjaink gyakorlati medicinájának egyik fontos, de sokszor bizony eléggé faragatlan talpköve.
Kiss, Róbert Gábor
core   +1 more source

Schlaganfallprävention bei Vorhofflimmern – Edoxaban als potenzielle neue Behandlungsmethode [PDF]

, 2011

openalex   +1 more source